Study finds lasting brain effects after trauma | Gene expression could guide metastatic colorectal cancer treatment | Palliative radiation may help some prostate cancer patients
June 24, 2015
CONNECT WITH SNMMI LinkedInFacebookTwitterYoutube
SNMMI SmartBrief
News for nuclear medicine and molecular imaging professionals

Top StoryAdvertisement
Study finds lasting brain effects after trauma
A study published in Clinical Psychological Science found that people who experienced trauma have increased responses in regions of the brain associated with emotions when recalling traumatic events. The researchers used functional MRI to scan the brains of eight passengers whose plane nearly crashed. Recalling the life-threatening experience significantly activated the amygdala, hippocampus, and midline frontal and posterior regions of their brains, as did recollection of the 9/11 terrorist attacks. People who had not experienced the near-crash did not have a similar response to recalling the 9/11 attacks. (6/23)
Share: LinkedInTwitterFacebookGoogle+Email
Webinar: Best Practices for Diagnostic Imaging Providers
With a focus on health care reform and its impact on the services, attendees will gain an understanding of the fundamental business decision making required to improve the profitability of their medical imaging practices. Join Wayne Webster, founder of Proactics Consulting, for this webinar on June 25th. Register for the webinar!
Clinical News & Research
Gene expression could guide metastatic colorectal cancer treatment
Metastatic colorectal cancer in patients who had low expression of the genes ERCC1 and TS, linked to DNA repair, responded to treatment with oxaliplatin, while the cancer responded to irinotecan at the same rate regardless of ERCC1 and TS expression level, researchers report in the journal PLOS ONE. The results suggest that irinotecan be considered first-line treatment for patients with high ERCC1 or TS gene expression and oxaliplatin is a better choice for those with low expression. Genetic Engineering & Biotechnology News (6/18)
Share: LinkedInTwitterFacebookGoogle+Email
Palliative radiation may help some prostate cancer patients
Palliative pelvic radiotherapy may help reduce urinary tract symptoms, macroscopic hematuria and pain for patients with castration-resistant prostate cancer and symptomatic pelvic tumors, researchers in Norway reported in the journal Radiotherapy and Oncology. The study found mild to moderate diarrhea was the most frequent side effect. Renal and Urology News (6/22)
Share: LinkedInTwitterFacebookGoogle+Email
Industry Report
French radiopharmaceutical maker secures $26M in financing
French radiopharmaceutical company Advanced Accelerator Applications announced that it has received $26 million from major U.S. investors including Adage Capital Management and funds and accounts associated with T. Rowe Price Associates and Rock Springs Capital Management. "This financing is a critical milestone for us, as we prepare for the Phase III trial results for Lutathera, and the continued progress of our molecular nuclear medicine pipeline," said AAA CEO Stefano Buono. BioSpace (San Francisco)/News release (6/23)
Share: LinkedInTwitterFacebookGoogle+Email
FDA grants orphan status to Vaxil Bio's mutiple myeloma treatment
Vaxil Bio's ImMucin, an immunotherapeutic agent designed to train the patient's immune system to attack multiple myeloma cells, has obtained orphan drug status from the FDA as a treatment for the disease. A Phase I/II trial is underway to assess the drug in metastatic breast cancer patients being treated with first-line hormone therapy. (6/22)
Share: LinkedInTwitterFacebookGoogle+Email
News from the Field
Many physicians interested in offering virtual visits, survey says
A QuantiaMD and American Well survey found that 57% of more than 2,000 primary care doctors are interested in having video visits with patients, compared with 12% who wouldn't offer the service. A flexible work-life schedule topped the reasons why participants would provide telehealth consultations, followed by additional income and better patient outcomes. (6/22)
Share: LinkedInTwitterFacebookGoogle+Email
Health Policy
SNMMI: CMS must address barriers to reimbursement for new tracers
SNMMI and other stakeholders have been working with the CMS to modernize the organization's approach to radiopharmaceutical reimbursement. The CMS restricted coverage of amyloid imaging in 2013, but in other cases fuller reimbursement has been the goal. However, existing pathways in Medicare's Hospital Outpatient Prospective Payment System do not support adequate payment, meaning providers lose money on procedures and may simply not perform them. (6/18)
Share: LinkedInTwitterFacebookGoogle+Email
Herbicide 2,4-D listed as possible carcinogen by world cancer agency
The World Health Organization's International Agency for Research on Cancer has found that the herbicide 2,4-D is a possible carcinogen for humans based in research in animals. Epidemiology research has not found a strong correlation between the herbicide and cancer, according to the agency. (6/23)
Share: LinkedInTwitterFacebookGoogle+Email
Advancing Health Care
Doctors beta-test smartphone tool to help patients with chronic pain
Physicians at Boston's Brigham and Women's Hospital are testing a smartphone application to improve the care offered to patients with chronic pain. Researchers designed the PMC 320 app to enable patients to send Fitbit data to providers and communicate with them about their health metrics. The Boston Globe (tiered subscription model) (6/22)
Share: LinkedInTwitterFacebookGoogle+Email
Just Released: The Highlights Lectures, 1981-2009
For more than three decades, Henry N. Wagner, Jr., MD, presented the annual Highlights Lecture at the SNM Annual Meeting. This new volume from SNMMI captures the Highlights Lectures from 1981 to 2009, as published in Newsline and The Journal of Nuclear Medicine. It presents a unique view of a pivotal 30 years in the history of nuclear medicine and molecular imaging through the eyes of one of the field’s most beloved pioneers. Pick up your limited edition, numbered copy today.
Share: LinkedInTwitterFacebookGoogle+Email
View 100 of the most popular sessions from SNMMI's 2015 Annual Meeting!
Purchase the SNMMI Virtual Meeting and get instant access to synchronized slides, audio and embedded video of 100 of the most popular sessions from SNMMI's 2015 Annual Meeting, including the Plenary Sessions and Henry N. Wagner, Jr., MD Highlights Symposium -- 40% more content than 2014! CME, ACPE and VOICE credits available. Learn more today.
Share: LinkedInTwitterFacebookGoogle+Email
The intellect of the wise is like glass: It admits the light of heaven and reflects it."
-- Augustus Hare,
Share: LinkedInTwitterFacebookGoogle+Email
The news summaries appearing in SNMMI SmartBrief are based on original information from multiple internet sources and are produced by SmartBrief, Inc., an independent e-mail newsletter publisher. The items above are not selected or reviewed by SNMMI prior to publication. Questions and comments may be directed to SmartBrief at
Subscriber Tools
Please contact one of our specialists for advertising opportunities, editorial inquiries, job placements, or any other questions.
Editor:  Melissa Turner
Advertising:  Meryl Harold
  P: 202.407.7828

Download the SmartBrief App  iTunes / Android
iTunes  Android
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004
© 1999-2015 SmartBrief, Inc.®
Privacy policy |  Legal Information